SAMSUNG EPIS HOLDINGS Co., Ltd.
Financials
Valuation Metrics
SAMSUNG EPIS HOLDINGS Co., Ltd.'s Market Cap is ₩8.2T. Ranked #79 of 2,421 in KR market (top 3%), #74 of 781 on KOSPI (top 9%), #4 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 2%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 8.21T KRW | KR#79/2,421 Sec#4/231 |
| Revenue | 251.69B KRW | KR#914/2,421 Sec#49/231 |
| Net Income | 85.31B KRW | KR#278/2,421 Sec#16/231 |
| Total Assets | 7.72T KRW | KR#139/2,421 Sec#3/231 |
| Net Assets | 5.91T KRW | KR#89/2,421 Sec#3/231 |
| Value | ||
| P/E | 96.25x | KR#1,483/2,421 Sec#101/231 |
| P/B | 1.39x | KR#1,725/2,421 Sec#119/231 |
| P/S | 32.63x | KR#2,361/2,421 Sec#192/231 |
| FCF Yield | -1.34% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 1.44% | KR#1,453/2,421 Sec#99/231 |
| ROA | 1.11% | KR#1,386/2,421 Sec#100/231 |
| Op. Margin | -25.29% | KR#2,156/2,421 Sec#151/231 |
| Financial Health | ||
| Debt Ratio | 30.64% | KR#604/2,421 Sec#70/231 |
| Total Debt | 377.00B KRW | KR#356/2,421 Sec#15/231 |
| FCF | -110.08B KRW | KR#2,140/2,421 Sec#211/231 |
| Cash | 131.30B KRW | KR#384/2,421 Sec#17/231 |
| Current Ratio | 1.36x | KR#1,315/2,421 Sec#138/231 |
| Performance | ||
| 1M Return | -9.22% | KR#2,061/2,421 Sec#173/231 |
| From 52W High | -57.31% | KR#1,755/2,421 Sec#132/231 |
| 1Y MDD | -55.85% | KR#1,254/2,421 Sec#103/231 |
| Trading | ||
| Volume | 27,223 shares | KR#1,434/2,421 Sec#143/231 |
| Trading Value | 9.01B KRW | KR#266/2,421 Sec#23/231 |
| Foreign Own. | 5.56% | KR#784/2,421 Sec#73/231 |
| Per Share | ||
| EPS | 3,429 KRW | KR#306/2,421 Sec#20/231 |
| BPS | 237,341 KRW | KR#58/2,421 Sec#1/231 |
Company Info
Samsung Episholdings is a bio investment holding company established in 2025, spun off from Samsung Biologics, and is engaged in biotechnology platform development. The company plans to intensively foster new businesses by leveraging its experience in growing its subsidiary, Samsung Bioepis, into a global top 5 biosimilar development company within 10 years through an R&D-focused biotech strategy. Samsung Bioepis has successfully developed and launched 11 biosimilar products, the most worldwide, demonstrating successful biosimilar development and commercialization. The company is headquartered in Yeonsu-gu, Incheon.